Sponsors
Sincere thanks to all sponsors of the COPD UK 2026 Conference for their valuable support!
Gold Sponsors
Bronze Sponsors
Special Collaborations
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.
With a proud 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. The company is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,700 employees work in research and development, manufacturing, supply, sales, and marketing. We supply around 36 different medicines to the NHS.
For additional information please visit: www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK
Declaration of Sponsorship. AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia.
Headquartered in Parma, Italy, Chiesi Farmaceutici is an international research-oriented biopharmaceuticals group with over 85 years’ experience in the pharmaceutical sector with 31 affiliates, employing over 7,000 people. Chiesi develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care.
The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
The Group’s research and development centre in Parma works alongside six other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. Chiesi Limited is headquartered in Manchester and employs over 400 people.
Further information: www.chiesi.uk.com
Declaration of Sponsorship. CHIESI Sponsorship is made through the purchase of exhibition space and/or sponsored speaker sessions.
SANOFI
Sanofi is an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine. We work to turn the impossible into the possible, providing life-changing treatment options and life-saving vaccine protection to millions of people worldwide – while placing sustainability and social responsibility at the heart of what we do.
Leading Pharmaceutical Innovations | Sanofi UK
REGENERON
Regeneron is a leading biotechnology company dedicated to inventing, developing and commercializing medicines for people with serious diseases. Our mission is to use the power of science to bring new medicines to patients … over and over again
Declaration of Sponsorship. SANOFI REGENERON has provided sponsorship towards this independent Programme and has had no involvement in its creation or organisation.
GSK are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030.
For additional information please visit: www.gsk.com/en-gb
Declaration of Sponsorship. This event is sponsored by pharmaceutical and healthcare companies who have contributed funding towards the event in return for exhibition space and/or sponsored speaker sessions.
Fisher & Paykel Healthcare is a global designer, manufacturer and marketer of respiratory products for use in acute and chronic respiratory care, surgery and treatment of obstructive sleep apnea (OSA).
Headquartered in New Zealand, we have for more than 50 years crafted humidification technologies to support individual respiratory needs across the healthcare spectrum.
F&P Healthcare and its more than 7000 employees have focused on developing innovative therapies that change clinical practice and help deliver a more sustainable healthcare service the world over. It has worked alongside healthcare professionals, knowing their clinical input is critical to success.
Today, our medical devices are used in the treatment of around 14 million patients in more than 120 countries each year, and the company remains unwavering in its drive to produce medical devices that improve the care, outcomes and quality of life of patients. For more information, please visit www.fphcare.com/en-gb
Philips Sleep & Respiratory Care (S&RC) is part of Philips, a global health technology company focused on improving people’s lives through meaningful innovation. S&RC is dedicated to helping people breathe easier and sleep better, across hospital, clinic and home care settings.
Resmed is a global pioneer in innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our ecosystem of cloud-connected medical devices help transform care for people with sleep apnoea, and other chronic diseases, while our digital health technologies drive new efficiencies in population health management.
The healthcare environment in the UK is evolving rapidly. As the population ages, chronic diseases are becoming more common. As a result, there is increased pressure on the healthcare industry and providers. Resmed is stepping up to the challenge and creating a future where healthcare is faster, more effective and more efficient. We’re connecting data, connecting patients and connecting healthcare to facilitate care and improve the therapy experience.
With more than 20.5 million cloud-connectable devices worldwide providing medical sleep and respiratory data, we are continuously working to reduce the impact of chronic disease and lower costs for consumers and healthcare systems.
Telemonitoring is particularly appropriate for the management of chronic, progressive conditions that require regular clinical follow-up, such as neuromuscular disease and chronic obstructive pulmonary disease (COPD).
AirView, our cloud-based patient monitoring system, connects to Resmed’s sleep, ventilation and high-flow therapy (HFT) devices so you can manage and support patients on these different treatments via the same platform.
Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.
Stirling Anglian Pharmaceuticals
Based in the UK, Stirling Anglian is committed to medicines optimisation. It has sourced and developed a portfolio of medicines to help the NHS curb waste – across a range of conditions that currently place unnecessary and avoidable pressure on NHS resources. At a time when there is such pressure on the NHS to reduce costs we believe we offer a real and practical solution.
We work closely with stakeholders across the NHS to identify real-world problems, and develop value-based solutions that support the delivery of efficient and cost-effective healthcare.
Company website www.stirlinganglianpharmaceuticals.com
TidalSenses vision is to transform COPD diagnostic pathways to drive efficiency and drastically improve patient care, through purposeful innovation grounded in cutting-edge science.
N-Tidal® Diagnose is a breakthrough CE-marked point-of-care diagnostic solution for COPD, which combines the precise measurement of respiratory physiology using the N-Tidal® medical device, and automated interpretation of the data using our diagnostic AI algorithms. From the start of the breath test, to accurate diagnosis with severity staging, in as little as 5 minutes.
For additional information please visit: tidalsense.com
Declaration of Sponsorship. TidalSense has provided sponsorship towards this independent Programme and has had no involvement in its creation or organisation.
Vapotherm are a global medical technology company focused on the development and promotion of our proprietary High Velocity Therapy products that are clinically indicated for patients of all ages suffering from respiratory distress caused by a range of pathologies including: asthma, bronchitis, CHF, COPD, dyspnoea and pneumonia or following prolonged mechanical ventilation.
Our High Velocity Therapy delivers non-invasive ventilatory support by providing heated, humidified, and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface.
Our Precision Flow and HVT 2.0 systems are clinically validated alternatives to, and address many limitations of, the current standard of care for the treatment of undifferentiated respiratory distress in a hospital setting. Randomised controlled trials have shown high velocity therapy to be non-inferior to NiPPV in preventing intubation for spontaneously breathing patients, from premature babies in the NICU to hypercapnic COPD patients experiencing moderate to severe acute exacerbations in the Emergency Department and the ICU.
PARI has been a trusted respiratory therapy brand for over a century and is passionate about working for a world where everyone can breathe freely. A global market leader in the respiratory sector, PARI has a portfolio of scientifically proven respiratory products including nebuliser devices, inhalation solutions and mucus clearance products.
Visit the PARI stand to find out how we are continually advancing therapies for respiratory diseases.
Link: www.pari.com
At Roche UK, we focus our energy and investment in developing tests and treatments...
Declaration of Sponsorship. Roche Products Ltd has provided financial support for this meeting but has had no involvement in the content.
TriOn Pharma Ltd.
TriOn Pharma is a dynamic UK-based company specializing in Nutraceuticals, Pharmaceuticals, and Medical Devices, committed to delivering innovative, high-quality, and cost-effective healthcare solutions that promote better health and well-being. As an ethical pharmaceutical partner, we collaborate closely with the NHS to provide value-driven products that support the optimization of drug budgets without compromising the quality of care. Our focus remains firmly on enhancing patient outcomes while upholding the highest standards in safety, efficacy, and compliance.
Declaration of Sponsorship
This event is sponsored by pharmaceutical and healthcare companies who have contributed funding towards the event in return for exhibition space and/or sponsored speaker sessions. Sponsorship funds have been used directly to support the delivery of the event including venue fees and daytime catering. No sponsorship funds have been used to support the evening dinner, nor the poster awards ceremony.
Sponsors have had no editorial input into or control over the agenda, content development or choice of neither speakers nor opportunity to influence except for the sponsored symposia presentations.
UK supporting Organisations:
